Oral agents and Outpatient Injections
FUNDING:
The Cancer Agency through funding from the government of Saskatchewan pays for all approved cancer drugs for patients with a valid health card and registered with the Cancer Agency. This includes drugs administered by injection or oral cancer treatments taken at home.
FORMULARIES:
Saskatchewan Drug Plan Formulary: Click Here
Saskatchewan Cancer Agency (SCA) Drug Formulary: Click Here
Exception Drug Status Program: Click Here
Drug (Brand Name) Manufacturer |
Indication | Strength, Route | DIN | Provincial Funding Eligibility Criteria | References | Patient Assistance Programs |
---|---|---|---|---|---|---|
Abiraterone (Zytiga) Janssen Inc. Generic | mCRPC | 250 mg tab | 500 mg tab |
Not specified |
Eligibility:
Notes:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Abiraterone (Zytiga) Janssen Inc. Generic | mCSPC | 250 mg tab | 500 mg tab |
Not specified |
Eligibility:
Notes:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Alendronate Generic | Osteoporosis | 10 mg PO | 70 mg PO |
Multiple |
Exception Drug Status Program1,2 Eligibility1,2:
OR
OR For treatment of osteogenesis imperfecta |
Apotex: Access Here |
|
Apalutamide (Erleada) Janssen Inc. | nmCRPC | Tablet, PO, 60mg, 240mg |
02478374 |
STEP special status* Eligibility1: nmCRPC in combination with ADT in patients who:
Apalutamide may continue until radiographic disease progression or unacceptable toxicity Notes: CRPC defined as 3 consecutive rises in PSA ≥1 week apart with the last PSA >2 mcg/L, during continuous ADT with castrate testosterone levels (<1.7 nmol/L) If biochemical progression (rising PSA) occurs while on apalutamide, appropriate clinical evaluation and/or investigations for metastatic disease should be conducted in a timely manner If progression to mCRPC occurs during apalutamide treatment for nmCRPC, abiraterone (not enzalutamide) is funded as a subsequent treatment option in patients who are unable to tolerate or are not candidates for other therapeutic choices (ie, chemotherapy) If apalutamide was discontinued in the nmCRPC setting (e.g., due to intolerance) prior to development of metastatic disease, either abiraterone or enzalutamide is funded as an option for treatment at the time of progression to mCRPC *STEP (SCA Treatment Evaluation Program) is a special status designation within the Cancer Agency which is an internal registration or approval process to support the ability of the P&T Committee to monitor drug program use when required. **60mg tablet funded, 240mg tablet pending provincial funding decision. |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Apalutamide (Erleada) Janssen Inc. | mCSPC | Tablet, PO, 60mg, 240mg |
02478374 |
Eligibility1: mCSPC in combination with ADT in patients who had no prior ADT in the metastatic setting or initiated ADT within 6 months in the metastatic setting with no disease progression Apalutamide may continue until radiographic disease progression or unacceptable toxicity Notes: Metastatic prostate cancer is interpreted as distant metastatic disease (ie, positive bone scan or metastatic lesions on radiologic imaging for soft tissue; patients with disease limited to regional pelvic lymph nodes only are not eligible) Patients who previously received adjuvant ADT in the non-metastatic setting are eligible as long as ADT was completed ≥1 year prior to initiation of apalutamide Patients who received recent docetaxel chemotherapy for the treatment of mCSPC within the past 3 months are eligible if they have not experienced disease progression Patients unable to tolerate apalutamide may be switched to either enzalutamide or abiraterone plus prednisone for treatment of mCSPC if there is no disease progression Patients who experience disease progression on apalutamide for treatment of mCSPC are eligible for abiraterone plus prednisone for treatment of mCRPC if they are unable to tolerate or are not candidates for other therapeutic choices (ie, chemotherapy) provided they have previously not experienced disease progression on abiraterone in any setting **60mg tablet funded, 240mg tablet pending provincial funding decision. |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Darolutamide (Nubeqa) Bayer | nmCRPC | 300 mg PO |
Not specified |
STEP special status* Eligibility1:
Notes:
*STEP (SCA Treatment Evaluation Program) is a special status designation within the Cancer Agency which is an internal registration or approval process to support the ability of the P&T Committee to monitor drug program use when required. |
|
NUBEQA® DART Patient Support Program: Toll free: 1-833-955-3278 Fax: 1-877-208-4393 Email:
|
Denosumab (Prolia) Amgen | Osteoporosis | 60 mg/ml Pre-filled Syringe |
02343541 |
Exception Drug Status Program1,2 Eligibility1,2:
Notes1,2:
|
ProVital Program: Access Here |
|
Denosumab (Prolia) Amgen | mCRPC + Bone mets | - |
- |
No listing as of Mar. 2022. |
- |
The VICTORY Program: Access Here |
Enzalutamide (Xtandi) Astellas | mCRPC | 40 mg cap |
Not specified |
Eligibility:
Notes: CRPC is defined as 3 consecutive rises in PSA ≥ 1 week apart with the last PSA >2 mcg/L, or progression or appearance of >2 lesions on bone scan or in soft tissue, during continuous ADT with castrate testosterone levels (<1.7 nmol/L) |
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
Enzalutamide (Xtandi) Astellas | nmCRPC | 40 mg capsule |
02407329 |
FUNDED INDICATIONS and ELIGIBILITY REQUIREMENTS: Non-metastatic castration-resistant* prostate cancer (nmCRPC) in combination with androgen deprivation therapy (ADT) in patients who:
Enzalutamide may continue until radiographic disease progression or unacceptable toxicity
FUNDING NOTES *Castration-resistant prostate cancer is defined as 3 consecutive rises in PSA at least 1 week apart with the last PSA >2 mcg/L, during continuous ADT with castrate testosterone levels (<1.7 nmol/L)
If biochemical progression (rising PSA) occurs while on enzalutamide, appropriate clinical evaluation and/or investigations for metastatic disease should be conducted in a timely manner
If progression to metastatic castration-resistant prostate cancer (mCRPC) occurs during enzalutamide treatment for nmCRPC, abiraterone is funded as a subsequent treatment option in patients who are unable to tolerate or are not candidates for other therapeutic choices (i.e., chemotherapy)
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
|
Enzalutamide (Xtandi) Astellas | mCSPC | 40 mg cap |
Not specified |
Eligibility:
Notes:
|
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. | mCRPC | Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate |
02538563 |
Pending provincial funding decision |
N/A |
Janssen BioAdvance Patient Assistance Program: Access Here |
Olaparib (Lynparza) AstraZeneca | mCRPC | 100 mg tab | 150 mg tab |
100mg: 02475200 | 150mg: 02475219 |
Metastatic castration-resistant prostate cancer (mCRPC) in patients with a deleterious or suspected deleterious germline and/or somatic mutation in the homologous recombination repair (HRR) genes BRCA or ATM, and who have experienced disease progression on or after prior treatment with androgen receptor axis targeted (ARAT) therapy, including patients who have stable brain metastases (if present).
Only documented mutations in BRCA1, BRCA2 and/or ATM that are known to be deleterious or suspected deleterious are eligible for olaparib; mutations described as non-detrimental (e.g., “variants of uncertain or unknown clinical significance” or “variant, favor polymorphism” or “benign polymorphism”) are not eligible. |
AstraZeneca Patient Support Program: Access Here |